Agenus (AGEN) vs Enanta Pharmaceuticals (ENTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Agenus (AGEN) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, gaining 78.1% versus a gain of 7.1%. Over five years, ENTA leads with a -82.7% price change compared with -92.7% for AGEN. Enanta Pharmaceuticals is the larger company by market cap ($352.4 million vs $340.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | ENTA |
|---|---|---|
| Share price | $7.54 | $12.10 |
| Market cap | $340.52M | $352.42M |
| 1-day change | -0.40% | -2.18% |
| YTD return | +141.08% | -23.27% |
| 1-year return | +78.12% | +7.08% |
| 5-year return | -92.74% | -82.69% |
| P/E ratio (TTM) | 2.98 | — |
| EPS (TTM) | $2.53 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $17.15 |
| 52-week low | $2.71 | $10.20 |
| Distance from 52-week high | -26.87% | -29.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +249.20% | +80.41% |
| Average volume | 4.26M | 226.58K |
| Shares outstanding | 45.16M | 29.13M |
| Employees | 81 | 120 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed ENTA by 71.0 percentage points over the past year.
- The two companies sit in different sectors: Agenus in Healthcare and Enanta Pharmaceuticals in Health Care.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Healthcare · Biotechnology · 81 employees
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
AGEN vs ENTA FAQ
Which is bigger, Agenus or Enanta Pharmaceuticals?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $352.42M compared with $340.52M for Agenus (AGEN).
Which stock has performed better over the past year, AGEN or ENTA?
AGEN returned +78.12% over the past 12 months, compared with +7.08% for ENTA (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Enanta Pharmaceuticals in the same industry?
No. Agenus is in the Healthcare sector, while Enanta Pharmaceuticals is in Health Care.